OTC:CPMV
Mosaic ImmunoEngineering Inc.
A pre-revenue biotech developer utilizing proprietary immunotherapy platforms to create next-generation cell therapies for oncology and autoimmune indications.
Key Metrics
Investment Thesis
Bull Case
Investors might consider CPMV if they believe in the high-impact potential of its proprietary Mosaic platform to disrupt the cell therapy landscape; the company's focus on oncology and autoimmune diseases addresses massive global market needs with high unmet patient demand; early-stage biotech stocks offer asymmetric upside potential if a key clinical milestone is achieved or a licensing deal is secured.
Bear Case
The stock carries extreme risk given the total liabilities of $6.9M against only $142k in total assets, creating a precarious balance sheet; consistent negative cash flow from operations and a growing deficit suggest the company cannot sustain its current burn rate without significant external funding; with zero revenue and no commercial products sold, there is no current cash generation to service debt or fund growth.
About Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering Inc. (CPMV) is a biotechnology firm focused on developing novel immunotherapy platforms to address unmet medical needs in oncology and autoimmune diseases. The company leverages its proprietary Mosaic platform to engineer next-generation cell therapies, targeting key markets including the United States and international clinical trial regions. Despite currently operating without commercial revenue, the firm is actively advancing its pipeline through strategic research and development expenditures.
Analysis
Management Discussion
Recent financial performance indicates intense cash burn driven by general and administrative expenses exceeding $695k and R&D costs of nearly $184k, resulting in a net loss of $922k for the latest period; while operating profit turned negative at -$880k, non-cash adjustments provided some relief to cash flow, though the company ended with a decline in cash reserves compared to the beginning of the year.
Industry Overview
The global immunoengineering and cell therapy market is expanding rapidly as therapeutic antibodies and engineered T-cells become standard treatments for cancer and autoimmune conditions; however, the sector remains capital-intensive with high failure rates in clinical trials requiring substantial R&D investment before any commercial return; companies like Mosaic must navigate complex regulatory pathways from agencies like the FDA to bring novel therapies to market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $2.6M | $1.4M | $879.7K |
| Operating Income | $-2.6M | $-1.4M | $-879.7K |
| R&D | $1.0M | $435.4K | $183.9K |
| G&A | $1.6M | $964.3K | $695.8K |
| Stock-Based Comp | $295.1K | $21.9K | $4.9K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $249.1K | $393.9K | $-39.9K |
| Pre-Tax Income | $-2.4M | $-1.0M | $-919.6K |
| Income Tax | $2.4K | $2.4K | $2.4K |
| Continuing Ops | $-2.4M | $-1.0M | $-922.0K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-2.4M | $-1.0M | $-922.0K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-2.4M | $-1.0M | $-922.0K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $261.3K | $179.5K | $141.6K |
| Cash & Equivalents | $220.6K | $156.2K | $115.0K |
| Other Current Assets | $40.6K | $23.4K | $26.6K |
| Long-Term Assets | $0 | $0 | $0 |
| Total Assets | $261.3K | $179.5K | $141.6K |
| Current Liabilities | $3.9M | $4.7M | $5.5M |
| Accounts Payable | $133.5K | $118.5K | $134.9K |
| Other Current Liab | $3.2M | $4.0M | $4.8M |
| Long-Term Liabilities | $1.2M | $1.3M | $1.4M |
| Total Liabilities | $5.1M | $6.1M | $6.9M |
| Shareholders' Equity | $-4.9M | $-5.9M | $-6.8M |
| Paid-In Capital | $2.0M | $2.0M | $2.1M |
| Retained Earnings | $-6.9M | $-7.9M | $-8.8M |
| Total L&E | $261.3K | $179.5K | $141.6K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-2.4M | $-1.0M | $-922.0K |
| Non-Cash Adjustments | $330.8K | $-299.7K | $73.4K |
| Working Capital Changes | $1.4M | $810.5K | $607.5K |
| Cash from Operations | $-690.1K | $-497.5K | $-241.2K |
| Cash from Investing | $343.0K | $433.0K | $0 |
| Debt Issuances | — | — | $270.0K |
| Cash from Financing | $341.6K | $0 | $200.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-5.5K | $-64.5K | $-41.2K |
| Beginning Cash | $226.1K | $220.6K | $156.2K |
| Ending Cash | $220.6K | $156.2K | $115.0K |
Frequently Asked Questions
How does Mosaic ImmunoEngineering Inc. make money?
The company operates primarily through a single focused segment dedicated to immunoengineering platform development, which encompasses all R&D activities, patent filings, and potential licensing arrangements for its proprietary technologies.
What are the main risks for CPMV?
The company faces significant financial risk due to substantial net losses, a large retained earnings deficit, and negative cash flow from operations over the last three years; as a pre-revenue entity with minimal current assets, CPMV relies heavily on external capital raises or financing activities to fund operations; potential dilution from future debt issuances or equity offerings is a constant threat to existing shareholders.
What is CPMV's competitive advantage?
Mosaic possesses a unique multi-antigen targeting technology that allows simultaneous engagement of multiple immune checkpoints; the firm holds a robust intellectual property portfolio protecting its core platform; management demonstrates deep expertise in cell therapy manufacturing and regulatory navigation.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.